Rafferty Asset Management
HRTX icon

Rafferty Asset Management’s Heron Therapeutics HRTX Stock Holding History

Rafferty Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-257,560
Closed -$901K – 1164
2024
Q2 		$901K Buy
+257,560
New +$791K ﹤0.01% 842
2022
Q4 		– Sell
-602,451
Closed -$2.54M – 1134
2022
Q3 		$2.54M Sell
602,451
-152,682
-20% -$597K 0.03% 457
2022
Q2 		$2.11M Sell
755,133
-196,954
-21% -$791K 0.02% 451
2022
Q1 		$5.45M Buy
952,087
+390,810
+70% +$2.86M 0.03% 368
2021
Q4 		$5.12M Buy
561,277
+293,809
+110% +$3M 0.03% 382
2021
Q3 		$2.86M Buy
267,468
+98,085
+58% +$1.19M 0.02% 510
2021
Q2 		$2.63M Sell
169,383
-27,309
-14% -$434K 0.02% 562
2021
Q1 		$3.19M Buy
196,692
+162,820
+481% +$2.9M 0.02% 451
2020
Q4 		$717K Sell
33,872
-75,112
-69% -$1.31M 0.01% 600
2020
Q3 		$1.61M Buy
108,984
+72,582
+199% +$1.13M 0.02% 476
2020
Q2 		$535K Buy
36,402
+25,952
+248% +$426K 0.01% 698
2020
Q1 		$123K Sell
10,450
-91,030
-90% -$1.71M 0.01% 552
2019
Q4 		$2.38M Sell
101,480
-17,085
-14% -$378K 0.04% 321
2019
Q3 		$2.19M Sell
118,565
-87,689
-43% -$1.61M 0.03% 330
2019
Q2 		$3.83M Buy
206,254
+77,812
+61% +$1.55M 0.07% 221
2019
Q1 		$3.14M Buy
+128,442
New +$3.36M 0.05% 216

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management's HRTX Position: Q3 2024 in Review

Rafferty Asset Management sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 257,560 shares — an estimated $901K sold.

Rafferty Asset Management first reported a position in HRTX in Q1 2019 and held it in 16 quarters. The position peaked at $5.45M in Q1 2022. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • Rafferty Asset Management reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 257,560 Heron Therapeutics shares in Q3 2024, an estimated $901K.
  • Rafferty Asset Management first reported a position in Heron Therapeutics in Q1 2019 and held it in 16 quarters.
  • Rafferty Asset Management's Heron Therapeutics position peaked at $5.45M in Q1 2022.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Rafferty Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.